CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and a rating upgrade by a Wall Street analyst. Though CRSP’s quarterly ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

Cathie Wood’s ARK ETFs capitalized on the pullback in Coinbase (COIN) and Robinhood (HOOD) stocks to load up additional shares on Thursday ...

But for what it's worth, Wall Street likes what it sees on the R&D side, with Citigroup ranking CRSP stock a "buy" and a consensus price target that is roughly 50% higher than current levels.